Bradács Alíz, Lorenzovici László, Bába László-István, Kaló Zoltán, Farkas-Ráduly Szabolcs, Precup Andreea Mihaela, Somodi Klementina, Gheorghe Maria, Calcan Alexandru, Tar Gyöngyi, Adam Ovidiu, Briciu Violeta Tincuta, Florescu Simin Aysel, Ianoși Edith Simona, Gârbovan Ovidiu, Siriopol Dimitrie Cristian, Vokó Zoltán
Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
"Dr. Mircea Pop" City Hospital Marghita, 415300 Marghita, Romania.
Healthcare (Basel). 2025 Apr 24;13(9):982. doi: 10.3390/healthcare13090982.
COVID-19 has impacted Romania's healthcare, economy, society, and public health. This study aims to evaluate the financial impact of the COVID-19 pandemic in Romania by analyzing both hospital costs and key elements of economic costs. The assessment was conducted from the perspective of the national payer. Hospital costs were analyzed covering two distinct timeframes: Q4 2020-Q3 2021 and Q1 2022-Q4 2022. The estimation of economic costs covered Q4 2020-Q3 2021. Hospital care costs were estimated using financial data from eight hospitals. The costs were extrapolated to inpatient data from 60 public hospitals for each of the two study periods. The disease burden was determined based on official data, including the number of confirmed cases, hospital bed occupancy, reported fatalities, and various cost components from an economic perspective. The findings indicate that the average hospital cost per patient episode was EUR 2267 (95% CI: 2137-2396) during the first period and EUR 2003 (95% CI: 1799-2207) in the second. The total national hospitalization expenses amounted to EUR 1.35 billion and EUR 730 million, respectively. When accounting for productivity losses and testing costs, the overall expenditure reached EUR 5.39 billion for Q4 2020-Q3 2021. In conclusion, the total economic burden of the COVID-19 pandemic in Romania by the end of 2021 was estimated at EUR 5.39 billion, encompassing hospitalization, isolation, premature deaths, quarantine, testing, and parental allowances. Despite the emergence of costlier treatment options, overall treatment costs declined, possibly due to increased vaccination rates. The study highlights the significant financial strain on the healthcare system and underscores the importance of evidence-based resource allocation to better manage future public health crises.
新冠疫情对罗马尼亚的医疗保健、经济、社会和公共卫生都产生了影响。本研究旨在通过分析医院成本和经济成本的关键要素,评估新冠疫情在罗马尼亚造成的财务影响。该评估是从国家付款人的角度进行的。医院成本分析涵盖了两个不同的时间段:2020年第四季度至2021年第三季度以及2022年第一季度至2022年第四季度。经济成本估算涵盖2020年第四季度至2021年第三季度。医院护理成本是根据八家医院的财务数据估算的。在两个研究期间,这些成本被外推至60家公立医院的住院患者数据。疾病负担是根据官方数据确定的,包括确诊病例数、医院床位占用情况、报告的死亡人数以及从经济角度来看的各种成本组成部分。研究结果表明,在第一个时期,每位患者每次住院的平均医院成本为2267欧元(95%置信区间:2137 - 2396欧元),在第二个时期为2003欧元(95%置信区间:1799 - 2207欧元)。全国住院总费用分别为13.5亿欧元和7.3亿欧元。在考虑生产力损失和检测成本后,2020年第四季度至2021年第三季度的总支出达到53.9亿欧元。总之,到2021年底,罗马尼亚新冠疫情的总经济负担估计为53.9亿欧元,包括住院、隔离、过早死亡、检疫、检测和育儿津贴。尽管出现了成本更高的治疗方案,但总体治疗成本有所下降,这可能是由于疫苗接种率提高所致。该研究凸显了医疗系统面临的巨大财务压力,并强调了基于证据的资源分配对于更好地应对未来公共卫生危机的重要性。